Please provide your email address to receive an email when new articles are posted on . BOSTON — New recommendations from ACP on type 2 diabetes treatment include adding a GLP-1 agonist or SGLT-2 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. GLP-1 agonists and co-agonists conferred better ...

Patients using GLP-1 agonists had a significantly lower hysterectomy rate over 2-year and 5-year follow-up. Women with nonmalignant uterine disease and a history of GLP-1 agonist and progestin ...

Experts at ISC 2026 highlighted growing evidence that GLP-1 receptor agonists may reduce stroke risk and support brain health through anti-inflammatory, vascular, and neuroprotective mechanisms.

U ntil recently, no treatments were available to help slow the progression of metabolic dysfunction–associated steatohepatitis (MASH), a severe form of fatty liver disease. But in March 2024, a ...

Among patients with type 2 diabetes, glucagon-like peptide 1 (GLP-1) receptor agonists reduced their risk of obesity-related cancers more than insulin did. Use of the drug class was also linked to a ...

About The Study: Glucagon-like peptide receptor agonists (GLP-1RAs) were associated with lower risks of specific types of obesity-associated cancers compared with insulins or metformin in patients ...

GLP 1 receptor agonists were associated with higher incident chronic cough in adults with type 2 diabetes, with risk persisting even after excluding patients with reflux diagnoses.